{"entity":{"id":"timothy-hughes","kind":"person","name":"Timothy P. Hughes","aka":[],"tldr":"Defined molecular response monitoring in CML and showed that many patients can safely stop imatinib.","summary":"Timothy Hughes led the molecular monitoring analyses of the IRIS trial that established BCR-ABL1 quantitative PCR and the International Scale as the way to track chronic myeloid leukaemia, and co-led ENESTnd (nilotinib) and the studies of treatment-free remission showing about half of patients in deep molecular response can stop tyrosine kinase inhibitors. He has chaired the International CML Foundation.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hughes%20TP%5BAuthor%5D%20chronic%20myeloid%20leukemia"}],"tags":["cml","molecular-monitoring","australia"],"related":[],"cancers":["cml"],"sections":[],"technologies":["mrd-testing","kinase-inhibitors"],"targets":[],"drugs":["imatinib"],"companies":[],"institutions":["royal-adelaide-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-iris-imatinib-nejm-2003"],"journals":[],"dependsOn":[],"notes":[],"role":"Consultant Haematologist, Royal Adelaide Hospital; Cancer Theme Leader, South Australian Health and Medical Research Institute","institutionId":"royal-adelaide-hospital","specialisms":["Chronic myeloid leukaemia","Molecular monitoring","Treatment-free remission","Tyrosine kinase inhibitors"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hughes%20TP%5BAuthor%5D%20chronic%20myeloid%20leukemia"}],"papers":[{"title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia (IRIS)","journal":"NEJM","year":2003,"doi":"10.1056/NEJMoa030513"},{"title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia (ENESTnd)","journal":"NEJM","year":2010,"doi":"10.1056/NEJMoa0912614"},{"title":"IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia","journal":"New England Journal of Medicine","year":2003,"url":"https://doi.org/10.1056/NEJMoa022457","doi":"10.1056/NEJMoa022457"}]},"route":"/people/timothy-hughes/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"}],"institution":[{"id":"royal-adelaide-hospital","kind":"institution","name":"Royal Adelaide Hospital","route":"/institutions/royal-adelaide-hospital/"}],"paper":[{"id":"paper-iris-imatinib-nejm-2003","kind":"paper","name":"IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia","route":"/key-papers/paper-iris-imatinib-nejm-2003/"}]}}